http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2123759-A2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_53453a9f0b5f6816736727b1130d042b |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2320-51 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-322 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-321 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-14 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-113 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-111 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-113 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-713 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7125 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-712 |
| filingDate | 2005-02-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f026631237de3545bf7b3152e3580541 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e4f7c5f44ede97badb4b8fb67b2010c1 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6a14c8bebf0fec5d430b4451c716c0ac http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c12a7957a79662b39338d7ba9116e780 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1f8ac3925199ed196ba9aaba5f0e5ffd http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2ef6b5e22cd0edb84c7af7e3d8ea2ccf |
| publicationDate | 2009-11-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EP-2123759-A2 |
| titleOfInvention | Stabilized RNAS as transfection controls and silencing reagents |
| abstract | RNA molecules, including siRNA molecules and related control, trackability and exaequo agents with specific stability modifications are provided. These molecules are particularly advantageous as transfection control reagents. The molecules include an RNA duplex comprising: n(a) a sense strand, wherein said sense strand comprises n(i) a first 5' terminal sense nucleotide and a second 5' terminal sense nucleotide, wherein said first 5' terminal sense nucleotide comprises a first 2'-O-alkyl sense modification and said second 5' terminal sense nucleotide comprises a second 2'-O-alkyl sense modification; n(ii) at least one 2'-O-alkyl pyrimidine modified sense nucleotide, wherein said at least one 2'-O-alkyl pyrimidine modified sense nucleotide is a nucleotide other than said first 5' terminal sense nucleotide or said second 5' terminal sense nucleotide; and n n(b) an antisense strand, wherein said antisense strand comprises n(i) a first 5' terminal antisense nucleotide and a second 5' terminal antisense nucleotide, wherein said first 5' terminal antisense nucleotide comprises a first 2'-O-alkyl antisense modification and said second 5' terminal antisense nucleotide comprises a second 2'-O-alkyl antisense modification; and n(ii) at least one 2'-O-alkyl pyrimidine modified antisense nucleotide, wherein said at least one 2'-O-alkyl modified antisense nucleotide is a nucleotide other than said first 5' terminal antisense nucleotide or said second 5' terminal antisense nucleotide, n nwherein the sense strand and antisense strand are capable of forming a duplex of between 16 and 50 base pairs. |
| priorityDate | 2004-02-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 501.